BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:obefazimod readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of obefazimod\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06456593-18@assetmemo.bio
DTSTAMP:20261121T003055Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:obefazimod: Phase 2 readout est. (NCT06456593)
DESCRIPTION:obefazimod\, phase 2\, Crohn's Disease.\nStudy: Efficacy and Sa
 fety of Obefazimod in Subjects With Moderately to Severely Active Crohn's 
 Disease\nEstimated primary completion: December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/obefazimod#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06456593
URL:https://assetmemo.bio/drug/obefazimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07453784-18@assetmemo.bio
DTSTAMP:20261121T003055Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:obefazimod: Phase 1 readout est. (NCT07453784)
DESCRIPTION:obefazimod\, phase 1.\nStudy: Study to Evaluate Pharmacokinetic
 s\, Relative Bioavailability\, Palatability of Obefazimod Minitablet Formu
 lation\nEstimated primary completion: April 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/obefazimod#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07453784
URL:https://assetmemo.bio/drug/obefazimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05177835-18@assetmemo.bio
DTSTAMP:20261121T003055Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:obefazimod: Phase 2 readout est. (NCT05177835)
DESCRIPTION:obefazimod\, phase 2\, Ulcerative Colitis.\nStudy: Long-term Sa
 fety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Ac
 tive Ulcerative Colitis\nEstimated primary completion: March 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/obefazimod#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05177835
URL:https://assetmemo.bio/drug/obefazimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
